GTPase activating protein fragments
US5763573A · kind A · utility
1Cited by
16References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 30, 1995 |
| Grant date | Jun 9, 1998 |
| Priority date | — |
| Expiry date | Jan 30, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Peptides, that inhibit GAP stimulated ras p21 hydrolysis of GTP; peptides that mediate dissociation of GDP from ras p21-GTP complex; and antibodies to the peptides are described. These peptides are useful as cancer diagnostics and therapeutics, particularly to detect cancer cells with an over expression of normal or oncogenic ras p21 protein and to treat cancer caused by ras oncogene. Methods for assaying products of oncogenes using the described peptides and antibodies are also disclosed. Method for treating cancer caused by ras oncogenes is also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.